Mar. 1 at 6:19 PM
It's been 5 months since the last commercial-stage oncology focused M&A transaction was announced
As seen on the attached history of comm'l-stage oncology focused M&A by month since 1/1/17, we've averaged ~5 exits/year over the last 3 years...& the current candidates
March - May has been an active period for M&A exits in this peer group the last 3 years. We guess the next bios in this peer group to exit, & relatively soon if history repeats itself, are;
1.
$SNDX via
$INCY There's countless reasons here on STs why a marriage is common sense (we thought the same by JPM but were wrong)
2.
$URGN
3.
$DAWN via Novartis. DAWN reported an impressive Q425 beat at JPM. However, DAWN is off ~12% since its corporate update suggesting the market does not approve of its business plan. We hope the BOD eventually puts S/Hs first
4.
$IOVA Much more to come. The 2 analysts that provide long-term IOVA forecasts only project
$1.2B in peak sales consistent with KYTH & DCPH. Both exited at ~
$2.1B in EV but...
